nContact Surgical Inc. is now nContact Inc.
The Morrisville, N.C.-based cardiac device manufacturer said its new name represents a move towards less invasive, endoscopic approaches for treating irregular heartbeat with epicardial ablation. The company’s surgical tools allow cardiologists to treat arrhythmias through a small midline abdominal incision, according to the company.
“By removing ‘Surgical’ from our company name, we are categorically affirming our mission to transform the ablation market and change the dialogue from individual surgical or catheter approaches to interdisciplinary and [epicardial]-only approaches that may achieve greater scientific and clinical endpoints,” CEO John Funkhouser said in prepared remarks.
The Power of One: Redefining Healthcare with an AI-Driven Unified Platform
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
In November, nContact raised $16 million in a Series D round to support its endoscopic cardiac ablation system for treating atrial fibrillation.
Related articles
- Atricure enrolls first patient in atrial fibrillation clinical trial (medcitynews.com)
- FDA approves Medtronic’s Artic Front therapy for irregular heartbeats (medcitynews.com)
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.